文献速递肿瘤 PET/CT核素与放射性配体治疗

基于容积68Ga-PSMA I&T PET/CT评估前列腺癌患者全身肿瘤负荷作为定量影像生物标志物的初步经验

Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.
PubMed 文献 · J Nucl Med · 2017-05-18

回顾性纳入101例根治性前列腺切除术后PSA升高并接受68Ga-PSMA I&T PET/CT的患者,计算PSMA衍生肿瘤体积(PSMA-TV)和总病灶PSMA(TL-PSMA)并与血清PSA比较;结果显示全身PSMA-TV和TL-PSMA与PSA显著相关(P<0.0001),而SUVmax(P=0.22)和SUVmean(P=0.45)不相关;10例治疗监测中,PSMA-TV和TL-PSMA变化与治疗反应/失败一致(P=0.02),SUVmax和SUVmean变化不一致(P=1.0)。

要点

  • 全身PSMA-TV和TL-PSMA与PSA水平显著相关(P<0.0001),SUVmax和SUVmean不相关。
  • 治疗反应与失败时,PSMA-TV和TL-PSMA变化与PSA变化一致(P=0.02)。
  • SUVmax和SUVmean变化与PSA变化不一致(P=1.0)。

核心结论

  • PSMA衍生容积参数可作为全身肿瘤负荷的定量影像生物标志物,能够标准化转移性前列腺癌PET影像的定量变化并促进治疗监测。

研究设计与样本

  • 回顾性分析纳入101例根治性前列腺切除术后PSA升高并接受68Ga-PSMA I&T PET/CT的患者。
  • 使用三维分割和计算机容积测量技术计算每位患者的PSMA-TV和TL-PSMA,并与血清PSA水平比较;在10例患者中应用容积参数进行治疗监测。

主要发现

  • 全身PSMA-TV和全身TL-PSMA与PSA水平(作为肿瘤负荷替代标志物)呈统计学显著相关(P<0.0001)。
  • SUVmax(P=0.22)和SUVmean(P=0.45)与PSA水平无统计学显著相关。
  • 治疗反应和治疗失败与全身PSMA-TV和全身TL-PSMA的一致变化平行(P=0.02)。
  • SUVmax变化(P=1.0)和SUVmean变化(P=1.0)均不与PSA水平变化一致平行。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A quantitative imaging biomarker is desirable to provide a comprehensive measure of whole-body tumor burden in patients with metastatic prostate cancer, and to standardize the evaluation of treatment-related changes. Therefore, we evaluated whether prostate-specific membrane antigen (PSMA) ligand PET/CT may be applied to provide PSMA-derived volumetric parameters for quantification of whole-body tumor burden. Methods: One hundred one patients who underwent 68Ga-PSMA I&T PET/CT because of increasing prostate-specific antigen (PSA) levels after radical prostatectomy were included in this retrospective analysis. Tracer uptake was quantified using SUVs. Volumetric parameters, that is, PSMA-derived tumor volume (PSMA-TV) and total lesion PSMA (TL-PSMA), were calculated for each patient using a 3-dimensional segmentation and computerized volumetry technique and compared with serum PSA levels. In a group of 10 patients, volumetric parameters were applied for treatment monitoring. Results: Volumetric parameters, that is, whole-body PSMA-TV and whole-body TL-PSMA, demonstrated a statistically significant correlation with PSA levels (P < 0.0001) as a surrogate marker of tumor burden, whereas SUVmax (P = 0.22) or SUVmean (P = 0.45) did not. Treatment response and treatment failure were paralleled by concordant changes in both whole-body PSMA-TV and whole-body TL-PSMA (P = 0.02), whereas neither the change in SUVmax (P = 1.0) nor the change in SUVmean (P = 1.0) concordantly paralleled changes in PSA levels. Conclusion: PSMA-derived volumetric parameters provide a quantitative imaging biomarker for whole-body tumor burden, capable of standardizing quantitative changes in PET imaging of patients with metastatic prostate cancer and of facilitating therapy monitoring.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schmuck S, von Klot CA, Henkenberens C, et al. Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. J Nucl Med. 2017. PMID: 28522740. doi:10.2967/jnumed.117.193581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。